Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).

Driving business growth through innovative food and nutrition strategies for CPG & foodservice brands. 💡 The Rise of GLP-1 ...

A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

TUESDAY, Nov. 19, 2024 (HealthDay News) -- More than half of all American adults, almost 137 million people, could be ...

“The results of this cohort study suggest that metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1 RA,” the authors write. “This appeared to be ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Tennessee's Medicaid program, TennCare, covers drugs like Ozempic and Mounjaro to treat those with diabetes and heart ...

The holidays are near, and so is the season of eating decadent meals – and sometimes, overeating. Overindulging on food is ...

The weight loss drug boom is here, and even retailers like Walmart are starting to feel the pressure to compete.

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Three-fourths of U.S. adults are now overweight or have obesity, with nearly 260 million predicted to have overweight or ...